Patents by Inventor Yoichi Furukawa

Yoichi Furukawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180222954
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
    Type: Application
    Filed: March 22, 2018
    Publication date: August 9, 2018
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
  • Patent number: 9975935
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: May 22, 2018
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
  • Publication number: 20160340398
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
    Type: Application
    Filed: August 4, 2016
    Publication date: November 24, 2016
    Inventors: TAKUYA TSUNODA, RYUJI OHSAWA, SACHIKO YOSHIMURA, TOMOHISA WATANABE, YUSUKE NAKAMURA, YOICHI FURUKAWA
  • Patent number: 9446106
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: September 20, 2016
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
  • Publication number: 20150290307
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
    Type: Application
    Filed: April 17, 2015
    Publication date: October 15, 2015
    Inventors: Takuya TSUNODA, Ryuji OHSAWA, Sachiko YOSHIMURA, Tomohisa WATANABE, Yusuke NAKAMURA, Yoichi FURUKAWA
  • Patent number: 9045557
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: June 2, 2015
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
  • Publication number: 20140134637
    Abstract: The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.
    Type: Application
    Filed: April 22, 2011
    Publication date: May 15, 2014
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Ryuji Hamamoto, Shuichi Nakatsuru
  • Patent number: 8674059
    Abstract: Objective methods for detecting and diagnosing colon cancer are described herein. In one embodiment, the diagnostic method involves determining the expression level of TOM34 that discriminates between colon cancer cells and normal cells. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of colon cancer, methods of treating colon cancer and method for vaccinating a subject against colon cancer.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: March 18, 2014
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Hideaki Tahara, Takuya Tsunoda, Satoshi Matsushima
  • Patent number: 8642724
    Abstract: Objective methods for detecting and diagnosing colon cancer are described herein. In one embodiment, the diagnostic method involves determining the expression level of TOM34 that discriminates between colon cancer cells and normal cells. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of colon cancer, methods of treating colon cancer and method for vaccinating a subject against colon cancer.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: February 4, 2014
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Hideaki Tahara, Takuya Tsunoda, Satoshi Matsushima
  • Publication number: 20130084578
    Abstract: Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. Also described are methods of treating and preventing breast cancer and breast cancer metastasis as well as methods of assessing the prognosis of a breast cancer subject and the efficacy of a breast cancer therapy. In one embodiment, the diagnostic method involves determining the expression level of ZNFN3A1, a gene whose expression is markedly elevated in breast cancers, that therefore can be used to discriminate between BRC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of BRC, methods of treating BRC and method for vaccinating a subject against BRC.
    Type: Application
    Filed: March 30, 2011
    Publication date: April 4, 2013
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Shuichi Nakatsuru
  • Patent number: 8354223
    Abstract: The present invention relates to methods for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of VEGFR1 by SMYD3. The invention further provides methods and pharmaceutical compositions for treating and preventing colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: January 15, 2013
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Ryuji Hamamoto, Shuichi Nakatsuru
  • Publication number: 20120190628
    Abstract: The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease.
    Type: Application
    Filed: October 22, 2010
    Publication date: July 26, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Hideaki Tahara, Takuya Tsunoda
  • Patent number: 8221993
    Abstract: The invention features a method for determining methyl transferase activity of a polypeptide and screening for modulators of methyl transferase activity. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer or hepatocellular carcinoma using the modulator.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: July 17, 2012
    Assignee: Onco Therapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa
  • Publication number: 20120149762
    Abstract: The present invention provides a novel human gene ZNFN3A1 whose expression is markedly elevated in a great majority of HCCs compared to corresponding non-cancerous liver tissues. The gene encodes a protein having a zinc finger domain as well as a SET domain and has been found to form a regulatory complex with RNA helicase and RNA polymerase.
    Type: Application
    Filed: February 23, 2012
    Publication date: June 14, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa
  • Publication number: 20120093845
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
    Type: Application
    Filed: March 15, 2010
    Publication date: April 19, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa watanabe, Yusuke Nakamura, Yoichi Furukawa
  • Patent number: 8148080
    Abstract: The present invention provides a novel human gene ZNFN3A1 whose expression is markedly elevated in a great majority of HCCs compared to corresponding non-cancerous liver tissues. The gene encodes a protein having a zinc finger domain as well as a SET domain and has been found to form a regulatory complex with RNA helicase and RNA polymerase.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: April 3, 2012
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa
  • Patent number: 8124341
    Abstract: The present application provides novel human genes WDRPUH and KRZFPUH, and PPIL1 whose expression is markedly elevated in a great majority of HCCs and colorectal cancers, respectively, compared to corresponding non-cancerous tissues, as well as novel human gene APCDD1 whose expression is elevated in primary colon cancers and down-regulated in response to the transduction of wild-type APC1 into colon-cancer cells. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: February 28, 2012
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa
  • Patent number: 7968281
    Abstract: The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: June 28, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Ryuji Hamamoto, Shuichi Nakatsuru
  • Patent number: 7939254
    Abstract: Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. Also described are methods of treating and preventing breast cancer and breast cancer metastasis as well as methods of assessing the prognosis of a breast cancer subject and the efficacy of a breast cancer therapy. In one embodiment, the diagnostic method involves determining the expression level of ZNFN3A1, a gene whose expression is markedly elevated in breast cancers, that therefore can be used to discriminate between BRC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of BRC, methods of treating BRC and method for vaccinating a subject against BRC.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: May 10, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Shuichi Nakatsuru
  • Patent number: 7871763
    Abstract: Genes up-regulated in hepatocellular carcinomas and polypeptides encoded by these genes are provided. Vectors, transformants and methods for producing the recombinant polypeptides are also provided. Probes and primers of these genes and antibodies against the polypeptides are also provided. The probes, primers and antibodies can be used as reagents for detecting hepatocellular carcinomas. Methods for detecting hepatocellular carcinomas using such detection reagents are further provided. Antisense nucleotide sequences of these genes are also provided and can be used to inhibit growth of hepatocellular carcinomas.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: January 18, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa